ELSE NUTRITION HOLDINGS announces that the Institutional Review Board has approved the infant growth study protocol for the testing of the Else Infant Formula. The infant growth study protocol was initially approved by the ethical committee and represents a critical step in the process of launching a new infant formula in the US. The infant growth clinical study is one of the critical stages in bringing Else Infant Formula to market, providing vital insights into the formula’s effectiveness and safety for infants. The IRB’s approval of the study protocol demonstrates the company’s commitment to delivering high-quality, sustainable, and safe nutrition solutions for families.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BABYF:
- Else Nutrition Receives IRB Approval for Infant Growth Clinical Study Protocol
- Else Announces Closing of First Tranche of Institutional Investment for Gross Proceeds of US$4.25M
- Else Nutrition announces investment for gross proceeds of up to $13.75M
- Else Announces Investment for Gross Proceeds of Up to US$13.75M
- Else Nutrition’s Kids Shakes Fastest Growing “Infant Formula & Toddler Nutrition Drink” in Natural Channel in 2022